PI3Kα/δ inhibition promotes anti-tumor immunity through direct enhancement of effector CD8+ T-cell activity
Larissa S. Carnevalli(AstraZeneca (Singapore)), Simon T. Barry(AstraZeneca (Singapore))
Cited by 87
Related Papers
Challenges and Key Considerations of the Enhanced Permeability and Retention Effect for Nanomedicine Drug Delivery in Oncology
|Cancer Research|2013|1.5k
Challenges and strategies in anti-cancer nanomedicine development: An industry perspective
|Advanced Drug Delivery Reviews|2016|1.1k
Assessing the Activity of Cediranib, a VEGFR-2/3 Tyrosine Kinase Inhibitor, against VEGFR-1 and Members of the Structurally Related PDGFR Family
|Molecular Cancer Therapeutics|2011|88
Landscapes of cellular phenotypic diversity in breast cancer xenografts and their impact on drug response
|Nature Communications|2021|59